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Abstract: Theranostic nanoparticles offer the potential for mixing and matching disparate 
diagnostic and therapeutic functionalities within a single nanoparticle for the personalized 
treatment of diseases. In this article, we present composite iron oxide-gadolinium-containing 




@GdPB) as a novel theranostic agent for T
1
-weighted 
magnetic resonance imaging (MRI) and photothermal therapy (PTT) of tumors. These 










nanoparticles function both as effective MRI contrast agents and PTT agents as determined 





@GdPB nanoparticles function as effective MRI contrast agents in vivo 
by increasing signal:noise ratios in T
1
-weighted scans of tumors and as effective PTT agents in 
vivo by decreasing tumor growth rates and increasing survival in an animal model of neuroblas-




@GdPB nanoparticles to function 
as effective theranostic agents.
Keywords: theranostics, Prussian blue, iron oxide, MRI, photothermal therapy, cancer
Introduction
Theranostics refers to the use of a diagnostic agent (Dx) in tandem with a therapeutic 
agent (Rx) for the personalized treatment of diseases.1 A well-known example of a 
commercialized theranostic is the use of HercepTest® (Agilent, Santa Clara, CA, USA) 
in combination with Herceptin® (Genentech, South San Francisco, CA, USA) for treat-
ing breast cancer.2 However, this approach requires the sequential administration of the 
paired Dx/Rx agents. A more desirable and potentially straightforward approach would 
be the simultaneous administration of the Dx/Rx agents to shorten procedure times 
while potentially improving patient comfort. Within this context, advances in the field 
of nanotechnology over the past few decades have facilitated the synthesis of nanopar-
ticles with diverse and complementary diagnostic and therapeutic properties that can 
be incorporated within a single theranostic nanoparticle.3,4 These include iron oxide 
nanoparticles,5,6 carbon nanotubes,7,8 gold nanorods,9,10 dendrimers,11,12 and vesicles,13,14 
of which multiple nanoparticles are already in the clinic.15,16 A key design criterion 
in the synthesis of theranostic nanoparticles, in addition to their complementary Dx/
Rx properties, is that the component materials of the nanoparticles are biocompatible 
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and/or safe for human use. Therefore, a compelling starting 
point would be to synthesize theranostic nanoparticles com-
posed of materials with a known safety profile.
To this end, in this study, we describe the design, syn-
thesis, and utilization of composite iron oxide-gadolinium-














, a US Food and Drug Administration (FDA)-approved 
material that has been used for T
2
-weighted (T2W) magnetic 
resonance imaging (MRI, in Combidex);16,17 Prussian blue, an 
FDA-approved material used in radiation poisoning treatment 
(as Radiogardase);18–20 and gadolinium, a key component 
of clinical MRI contrast agents including Magnevist and 
Gadovist.21,22 Earlier reports have described the synthesis of 
magnetic Prussian blue nanoparticles (without gadolinium) 
for T2W imaging combined with photothermal therapy (PTT) 
of tumors and gene transfection or chemotherapy combined 
with PTT of tumors.23–25





GdPB nanoparticles for magnetically guided, T
1
-weighted 
(T1W) imaging and PTT of tumors. Compared with T2W 
images, T1W images offer several advantages including 
enhanced visualization of vascular structures, key for the 
entry of Dx and Rx agents into tumors, and are less prone 
to artifacts such as those present in fluid-filled structures in 
particular.26 Under external magnetic guidance, T1W images 
offer the potential to visualize the entry of the composite 
Dx/Rx agents into a tumor through its vasculature in real-
time, allowing for a more precise administration of PTT 
to targeted tumors. This approach can facilitate improved 
tumor treatment margins, which has implications not only for 
local tumor control but also in prevention of its recurrence.
In seeking to leverage these aforementioned advantages, 





@GdPB nanoparticles. We determine the MRI and pho-
tothermal properties of the nanoparticles. Finally, as a proof-




@GdPB nanoparticles for 
T1W MRI and PTT in an animal model of neuroblastoma,27,28 
a prevalent solid tumor of childhood and a leading cause of 
cancer-related death in children.29,30 The findings of our study 
are crucial for further developing our composite theranostic 
nanoparticles for magnetically targeted, image-guided pho-
tothermal destruction of tumors.
Materials and methods
Materials
Ultrapure water used in this study was obtained from a 
Milli-Q® system (MilliporeSigma; resistivity $17.8 MΩ cm). 
All chemicals were purchased from Sigma-Aldrich, and 
biological reagents were purchased from Thermo Fisher 
Scientific and used as supplied without further purification 
unless noted otherwise.





@GdPB nanoparticles were synthesized using a scheme 
modified from previously described studies.23–25 Briefly, 





where a 1:2 molar ratio of Fe2+:Fe3+ was added dropwise 





 nanoparticles was thoroughly 
rinsed and dispersed in ultrapure water by centrifugation (at 
least three times at 22,000× g for 10 minutes) and resuspen-





 nanoparticles (diluted to 1 mg/mL) were added dropwise 




] (2 mM; pH =3) in a sonicator 
bath with continuous stirring maintained at 50°C. The above-







 (2 mM; pH =3) under the sonication, 
stirring, and heating conditions described earlier. Finally, the 




@GdPb nanoparticles was 
rinsed and dispersed in ultrapure water as described earlier.
characterization of the Fe3O4@gdPB 
nanoparticles
The size (hydrodynamic diameter) and charge (zeta poten-




@GdPB nanoparticles were 




 and GdPB nanoparticles (previ-
ously synthesized by us)32,33 using dynamic light scattering 
on a Zetasizer Nano ZS (Malvern Instruments, Malvern, 




@GdPB nanoparticles in 
ultrapure water was assessed by measuring their hydrodynamic 
size distributions every 24 hours over 5 days using dynamic 
light scattering. The visible-near infrared (NIR) spectra of 
1 mg/mL suspensions of the three different types of nano-
particles in ultrapure water were measured using a Genesys 
10S Ultraviolet-Visible (UV-Vis) spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA). Transmission electron 









nanoparticles were obtained by loading 5 µL of the nano-
particle suspensions separately onto copper grids (Electron 
Microscopy Sciences, Hatfield, PA, USA) using a JEOL 
JEM 2100 field-emission gun scanning transmission electron 
microscope (TEM; JEOL, Peabody, MA, USA). Analysis of 
the size distributions of the nanoparticles was performed using 
ImageJ (National Institutes of Health). Energy-dispersive 
X-ray spectroscopy (EDS) was performed using an INCA 
250 analysis system (Oxford Instruments, Abingdon, UK) 
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composite iron oxide–Prussian blue nanoparticles for cancer theranostics
on different parts of the grid and then averaged to obtain the 
relative percentages of Gd, Fe, and K.
MrI properties of the Fe3O4@gdPB 
nanoparticles




@GdPB nanoparticles were 
measured using a clinical horizontal 3 T magnet (GE Health-
care, Chicago, IL, USA). Phantoms containing varying concen-









were prepared in 96-well plates in 0.5% agarose solutions. A 
constant temperature of 23°C was maintained for all the mea-
surements. The phantoms were placed on a 2% solid block of 
agar and secured by tape at the center of an 8-channel high defi-




 relaxation times were measured in 
the same coronal 0.5 mm thick slice. Inversion times (TI) were 
varied (from 50 to 4,000 ms) to obtain T
1
 measurements, while 
echo times (TE) were varied (from 12 to 245 ms) to obtain T
2
 
measurements. Image processing software, OsiriX, was used 
to analyze the signal intensity within a region of interest (ROI) 
of the acquired images. To measure the T
1
 inversion, the signal 
intensity was plotted against the TI values, while signal intensity 
was plotted against TE values for the T
2
 decay curves. The data 
were then fitted using the following equations:


























where SI is the signal intensity within the ROI, and A, B, and 




 relaxation rates were 




, respectively. The 
relaxation rates obtained were plotted against the concentra-
tions of the corresponding contrast agent (Gd for T1W images 
and Fe for T2W images) and slopes of these plots yielded 
the relaxivities of the nanoparticles.
Photothermal properties of the Fe3O4@
gdPB nanoparticles





ticles were measured using aqueous dispersions of the nano-
particles irradiated using an 808 nm NIR laser (Laserglow 
Technologies, Toronto, Canada), as previously described.35 





were measured as a function of concentration by varying the 
concentration of the nanoparticles from 0.01 to 0.2 mg/mL 
at a fixed laser fluence (power density) of 1.875 W/cm2 for 
10 minutes. The PTT capabilities were measured as a function 





@GdPB for 10 minutes. The stability of the 
nanoparticles as a photothermal agent was assessed by a cyclic 





diated by the NIR laser (laser on/off times =10 minutes each). 





nanoparticles was measured by first heating 0.1 mg/mL of the 
nanoparticles with the NIR laser at a fluence of 1.875 W/cm2 
for 10 minutes. The laser was then turned off, and the cooling 
kinetics of the nanoparticles was measured as a function of 
time. The photothermal conversion efficiency was calculated 







hA (T T ) Q
I (1 10 )  
Where h is the heat transfer coefficient, A is the surface area 
of heat transfer of the system, T
max
 is the maximum system 
temperature, T
amb
 is the ambient temperature, Q
0
 is the rate 
of heat input due to absorption of light energy by water, I is 





@GdPB at 808 nm.
Intrinsic and PTT-induced cytotoxicity 
of the Fe3O4@gdPB nanoparticles





GdPB nanoparticles in vitro was measured using the murine 
neuroblastoma cell line Neuro2a (ATCC). Briefly, Neuro2a 
was seeded in 96-well plates and incubated with either 





particles (0.01–0.5 mg/mL) with or without laser irradiation 
using the NIR laser (1.5 W/cm2; 10 minutes). Twenty-four 
hours after the treatment, cell viability was assessed using 
the CellTiter-Glo luminescent cell viability assay (Promega 
Corporation, Madison, WI, USA). Each treatment was con-
ducted with at least three replicates.
animals
All animal studies were conducted in accordance with pro-
tocols approved by the Institutional Animal Care and Use 
Committee (IACUC) at Children’s National Health System 
and were conducted to ensure humane care of the animals 
as per the IACUC’s guidelines. For the animal studies, 
4–6-week old female A/J mice were purchased from Jackson 
Laboratory, and the animals were acclimated for 3–4 days 
prior to commencing the studies.
animal studies
To establish the murine neuroblastoma model, one million 
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injected subcutaneously into the shaved backs of 4–6-week 
old female A/J mice. Tumor growth was monitored by routine 
caliper measurements, as previously described.35,37 All treat-
ments commenced only after the Neuro2a tumors reached 
a diameter of at least 5 mm (~60 mm3). Tumor-bearing 
mice were divided into three groups (n$9 mice/group): 














@GdPB + magnet group: 




@GdPB by tail vein 
injection followed by application of an external magnetic 
field for 10 minutes; by externally affixing a 3,000 Gauss 
magnet (0.25″×0.25″×0.25″ Nickel-plated neodymium; 
K&J Magnetics Inc, Pipersville, PA, USA) to the surface of 
the tumors for mice in this group. After this step, the mice 
in each group were divided into two cohorts (n$4 mice/
cohort). Mice in cohort 1 were used for MRI. These mice 
were immediately euthanized after the aforementioned pro-
cedures and their tumors extracted. Tumor phantoms were 
prepared using 5% agarose solutions and T1W images of 
these tumors were acquired and analyzed as described earlier. 
Mice in cohort 2 were used for PTT. These mice were irradi-
ated after completing application of the external magnet with 
the NIR laser (1.5 W/cm2; 15 minutes). The tumor surface 
temperature achieved during the laser treatment step was 
measured using an i7 thermal camera (FLIR, Wilsonville, 
OR, USA). Post-PTT, tumor growth, and animal survival 
were monitored.
statistical analysis
Statistically significant differences between groups were 
determined by using a Student’s t-test. The log-rank test 
was used to determine statistically significant differences 
in survival, analyzed by generating Kaplan–Meier plots. 
A P-value of ,0.05 was considered statistically significant 
in all studies (denoted by *).
Results and discussion
synthesis scheme yields Fe3O4@gdPB 
nanoparticles with stable, monodisperse 






@GdPB nanoparticles were synthesized by 
growing a “shell” of gadolinium-containing Prussian blue on 
an iron oxide nanoparticle “core” by modifying previously 
published schemes for synthesizing magnetic Prussian blue 
nanoparticles (without gadolinium).23–25 This synthesis relies 
on the attachment of Fe(CN
6
)4- onto the surface of iron oxide 
nanoparticles at an acidic pH (refer “Materials and methods” 
section for details), and the subsequent growth of a GdPB 
shell by the reaction of Fe(CN
6
)4-, Fe3+, and Gd3+ on the 
surface of the iron oxide nanoparticles. To determine the 




@GdPB nanoparticles synthesized 
using the presented two-step scheme (Figure 1A), we first 
measured the size distributions and charges of the nanopar-






sity index ~0.2) with a mean hydrodynamic diameter of 
164.2 nm, which was higher than the mean hydrodynamic 




 (68 nm) and GdPB (91 nm) 
nanoparticles (Figure 1B). Zeta potential measurements 




@GdPB nanoparticles exhibited 





 (-13.3 mV) and GdPB (-24.8 mV) nanoparticles 
(Figure 1C). Multiday stability studies using dynamic light 





@GdPB nanoparticles retained nearly constant size dis-
tributions over 5 days (Figure 1D). Visible-NIR spectroscopy 














GdPB retained the characteristic absorption band of Prussian 
blue-based nanoparticles (GdPB) in the 600–900 nm range 
and, as expected, demonstrated an attenuated absorption band 





@GdPB nanoparticles (Figure 2A) with a size 





 core nanoparticles (without GdPB) that had a size 
range of 8.0±2.2 nm (Figure S1). EDS scans conducted on 
seven different areas of the TEM grid revealed that the ana-
lyzed nanoparticles comprised both Fe and Gd (Figure 2B). 
Taken together, these findings demonstrate that our synthesis 




@GdPB nanoparticles with 






Fe3O4@gdPB nanoparticles function as 
effective MrI contrast agents




@GdPB nanoparticles function 
as effective MRI contrast agents, we conducted scans of 









 and GdPB nanoparticles in a clinical 





@GdPB nanoparticles generated increased contrast 
in a concentration-dependent manner (Figure 3A), ie, 
increased brightening at increased concentrations, similar 
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composite iron oxide–Prussian blue nanoparticles for cancer theranostics
Figure 1 synthesis and characterization of Fe3O4@gdPB nanoparticles.
Notes: (A) The two-step scheme employed for synthesizing Fe3O4@gdPB nanoparticles. (B) Dynamic light scattering-based analysis of the size distributions (hydrodynamic 
diameters) of Fe3O4, gdPB, and Fe3O4@gdPB nanoparticles. (C) Zeta potentials of Fe3O4, gdPB, and Fe3O4@gdPB nanoparticles. (D) Multiday mean sizes (hydrodynamic 
diameters) of Fe3O4@gdPB nanoparticles measured by dynamic light scattering. (E) Visible-near infrared spectra of 1 mg/ml each of Fe3O4, gdPB, and Fe3O4@gdPB 
nanoparticles.
Abbreviations: Fe3O4@gdPB, composite iron oxide-gadolinium-containing Prussian blue; Fe3O4, iron oxide; gdPB, gadolinium-containing Prussian blue; MrI, magnetic 
resonance imaging; PBNP, Prussian blue nanoparticle; T1W, T1-weighted.
Figure 2 shape and composition of Fe3O4@gdPB NPs.
Notes: (A) Transmission electron microscopy image of Fe3O4@gdPB NPs. (B) representative energy-dispersive X-ray spectrum of Fe3O4@gdPB NPs. The composition 
was derived by built-in software from the attribution of the electronic energy profile for Fe, K, and Gd.
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 =5.5 mM-1 s-1 and r
2
 = 126 mM-1 s-1. 
Although the r
1




@GdPB is lower than that 
of GdPB (38.4 mM-1 s-1), it is in a range similar to most 
clinically approved, gadolinium-based T
1
 contrast agents at 
a field strength of 3 T, including Magnevist (3.1 mM-1 s-1), 
ProHance (2.8 mM-1 s-1), and Omniscan (3.2 mM-1 s-1).22 




@GdPB is that 
they can be guided to a particular anatomical location by an 
external magnetic field, which cannot be achieved using GdPB 
nanoparticles that have to rely on vasculature for anatomical 





@GdPB can be appropriately modified to 
incorporate a larger shell of GdPB with increased loading 









@GdPB can function as an 
effective MRI contrast agent in T1W scans. In parallel with 
these studies, we analyzed the T
2





nanoparticles and obtained an r
2
 value of 126 mM-1 s-1 at a 
3 T field strength. Although we do not explicitly utilize the 
T
2




@GdPB nanoparticles in this study, 
since the proposed use of our nanoparticles is for PTT of 
tumors and we have previously discussed the limitations of 
using T2W images especially for fluid-filled structures, our 
results demonstrate that there may be future potential of these 
agents as contrast agents in T2W imaging applications.
Fe3O4@gdPB nanoparticles function as 
effective PTT agents





GdPB nanoparticles, we measured their heating as a function 
of concentration, laser fluence, and multiple cycles of heating 
and cooling. At a constant laser fluence of 1.875 W/cm2, the 
nanoparticles were observed to heat to significantly higher 
temperatures over the background (water; Figure 4A) with 
changes in temperature approaching 20°C at a nanopar-
ticle concentration of 0.01 mg/mL and ~35°C at nanoparticle 
concentrations $0.05 mg/mL. At a constant nanoparticle 




@GdPB was observed to 
heat to higher temperatures in a laser fluence-dependent man-
ner (Figure 4B). Additionally, the nanoparticles retained their 
photothermal heating properties over four cycles of heating 
and cooling (Figure 4C) indicating their stability as photo-
thermal agents over multiple heating cycles. Finally, studies 
conducted to calculate the photothermal conversion efficiency 
(Figure 4D) demonstrated that the nanoparticles had a photo-
thermal conversion efficiency of 16.1%, which is consistent 
with the previously determined photothermal conversion effi-
ciency of Prussian blue nanoparticles (around 20%)35 despite 
Figure 3 MrI properties of Fe3O4@gdPB nanoparticles.
Notes: (A) T1W Mr images of gdPB and Fe3O4@gdPB nanoparticles. (B) T2W 
Mr images of Fe3O4 and Fe3O4@gdPB nanoparticles. (C–D) T1-relaxation rate (1/
T1), as a function of gd
3+ concentration (mM) in (C) gdPB and (D) Fe3O4@gdPB 
nanoparticles. (E–F) T2-relaxation rate (1/T2) as a function of Fe concentration 
(mM) in (E) Fe3O4 and (F) Fe3O4@gdPB nanoparticles. (G) relaxivities of Fe3O4, 
gdPB, and Fe3O4@gdPB nanoparticles.
Abbreviations: Fe3O4@gdPB, composite iron oxide-gadolinium-containing 
Prussian blue; Fe3O4, iron oxide; gdPB, gadolinium-containing Prussian blue; l-r, 
left-to-right; MrI, magnetic resonance imaging; T1W, T1-weighted; T2W, T2-
weighted; nd, not determined for this study.





@GdPB nanoparticles generated increased contrast 
in a concentration-dependent manner (Figure 3B), ie, 





 nanoparticles, which have been well-described 
in the literature.5,6 Based on image processing of multiple 
T1W and T2W scans, we generated relaxation time plots as 
a function of the contrast agent, namely Gd3+ ions for GdPB 
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GdPB nanoparticles are stable and effective PTT agents.
Fe3O4@gdPB nanoparticles are 
cytotoxic to targeted cells upon 
photothermal heating





nanoparticles as well as test whether they can function as effec-
tive PTT agents in the presence of cells, we added varying con-
centrations (0.01–0.5 mg/mL) of the nanoparticles to Neuro2a 
cells (which will be used in our animal studies) in vitro, with and 





@GdPB nanoparticles exhibit marginal intrinsic 
toxicity (in the absence of NIR laser irradiation) to Neuro2a 





Figure 4 Photothermal heating properties of Fe3O4@gdPB nanoparticles.
Notes: (A) Photothermal heating of varying concentrations of Fe3O4@GdPB nanoparticles at a constant laser fluence of 1.875 W/cm
2 for 10 minutes. (B) Photothermal 
heating of 1 mg/ml Fe3O4@GdPB nanoparticles as a function of varying 808 nm NIR laser fluence for 10 minutes. (C) Temperature profiles during cyclic heating of 1 mg/mL 
Fe3O4@GdPB nanoparticles using an 808 nm NIR laser (laser on/off time: 10 minutes each). (D) generation of heating and cooling curves of Fe3O4@gdPB nanoparticles to 
calculate their photothermal conversion efficiency.
Abbreviations: Fe3O4@gdPB, composite iron oxide-gadolinium-containing Prussian blue; NIr, near infrared.
Figure 5 Intrinsic and PTT-induced cytotoxicity of varying concentrations of 
Fe3O4@gdPB nanoparticles on Neuro2a cells in vitro.
Abbreviations: Fe3O4@gdPB, composite iron oxide-gadolinium-containing 
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was slightly decreased to ~80% of the vehicle-treated controls 
at these concentrations, suggesting that the nanoparticles can 
be safely used for PTT of cells without intrinsic cytotoxicity 
at concentrations lower than 0.1 mg/mL. Upon irradiation 





ated significantly increased cytotoxicity to Neuro2a cells with 
cell viability decreasing to ,60% of controls at nanoparticle 
concentrations $0.1 mg/mL (under the experimental condi-




@GdPB concentration of 0.5 mg/mL, cell 
viability was observed to decrease 3.5-fold to around 25% 
upon irradiation compared to 80% viability in the absence of 





@GdPB nanoparticles do not exhibit intrinsic 
cytotoxicity as well as demonstrate that the nanoparticles 
retain their PTT properties in the presence of targeted cells.
Fe3O4@gdPB nanoparticles function as 
effective contrast agents in T1W imaging of 
tumors in a mouse model of neuroblastoma





GdPB nanoparticles as effective theranostic agents in vivo, 
we tested the ability of the nanoparticles to function as 
MRI contrast agents in an animal model of neuroblastoma. 
Specifically, mice bearing palpable subcutaneous Neuro2a 
tumors (average tumor size $5 mm) were divided into three 





@GdPB-treated: tumor-bearing mice were 





GdPB + magnet-treated: tumor-bearing mice were tail-vein 
injected with the nanoparticles and an external magnetic 
field was applied over the tumor for 10 minutes to direct 
the circulating nanoparticles into the tumor. T1W scans 
(Figure 6) of extracted tumor phantoms demonstrated that 




@GdPB + magnet-treated 
group exhibited increased contrast, ie, increased signal:noise 





@GdPB-treated groups (Figure 6A). Tumors 




@GdPB + magnet-treated group 
exhibited an average signal:noise ratio of around 3.2, which 
was significantly higher (P,0.05) than tumors from the 





groups. Although further T1W imaging studies in a live 





@GdPB nanoparticles can function as 
effective contrast agents for T1W imaging of tumors in the 
presence of external magnetic guidance. Our studies repre-
sent an important first step toward achieving this important 
end goal of T1W resolution of tumors.
Fe3O4@gdPB nanoparticles function as 
effective PTT agents in a mouse model 
of neuroblastoma
Complementary to the T1W imaging studies, we conducted 





particles in the Neuro2a mouse model of neuroblastoma. Neu-
ro2a tumor-bearing mice (average tumor size $5 mm) were 
divided into three groups (n=5/group): 1) untreated: receiving 










@GdPB + magnet-treated: where tumor-bearing 
mice were tail-vein injected with the nanoparticles, and an 
external magnetic field was applied over the tumor for 10 min-
utes to direct the circulating nanoparticles into the tumor. 
Shortly after application of the external magnet, tumors of 









+ magnet-treated group were irradiated with the NIR laser 
(Figure 7). Tumor surface temperatures as measured by 





GdPB + magnet-treated group achieved an average tumor 
surface temperature of 52°C after 10 minutes of irradiation, 
Figure 6 T1W imaging characteristics of Fe3O4@gdPB nanoparticles in a Neuro2a 
tumor model.
Notes: (A) ex vivo signal:noise ratio measured in T1W images of tumors harvested 
from untreated, Fe3O4@gdPB-treated, and Fe3O4@gdPB + magnet-treated 
Neuro2a tumor-bearing mice showing significantly higher signal:noise ratio only in 
the presence of both the Fe3O4@gdPB nanoparticles plus magnet (*P-value ,0.05). 
(B) raw T1W images of tumors harvested from untreated, Fe3O4@gdPB-treated, 
and Fe3O4@gdPB + magnet-treated Neuro2a tumor-bearing mice.
Abbreviations: Fe3O4@gdPB, composite iron oxide-gadolinium-containing 
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which was marginally higher than the tumor surface tem-





(Figure 7A). Furthermore, both groups achieved tumor sur-
face temperatures that were on average .20°C above the ini-
tial tumor surface temperatures (~25°C). Our observations of 
significantly elevated temperatures over basal temperatures 




@GdPB-treated group are not unexpected 
given that our previous studies in the same Neuro2a model 
have demonstrated that NIR irradiation of tumors even in the 
absence of PTT agents can elevate tumor surface tempera-
tures by 5°C–10°C.35 Additionally, when using nanoparticle-
based PTT agents particularly at short time intervals after 
tail-vein injection (ie, ,1 h), further heating is caused by 
nanoparticles circulating through tumor vasculature that are 
irradiated by the laser (intravascular heating). The addition of 
magnet concentrates a larger amount of nanoparticles within 










GdPB-treated. Strategies that can be employed to increase 










are to apply the external magnet for longer periods of time, or 
wait until the majority of the nanoparticles are cleared from 
circulation (typically 1–2 hours, unless the nanoparticles are 
specifically designed for longer circulation times).
Kaplan–Meier survival plots demonstrated that mice 









GdPB + magnet-treated group exhibited significantly higher 
survival than the mice in the untreated group as deter-





@GdPB + magnet-treated group exhibited marginally 





treated group although this was not statistically significant. 
Further optimization studies with increased power, ie, 
increased number of mice per group, are required to com-
pletely characterize the observed PTT effects and their 
implications for animal survival. Finally, tumor growth 









@GdPB + magnet-treated groups 
causes slower tumor progression as evidenced by the lower 
tumor growth curve slopes relative to mice in the untreated 





magnet-treated group appeared to be marginally slower than 




@GdPB-treated group but this was not 
°
Figure 7 Photothermal therapy characteristics of Fe3O4@gdPB nanoparticles in a Neuro2a tumor model.
Notes: (A) Tumor temperatures as a function of time measured by an infrared thermal camera in Neuro2a tumor-bearing mice that are treated with either Fe3O4@gdPB 
nanoparticles or Fe3O4@gdPB nanoparticles + magnet. (B) Kaplan–Meier survival curves of Neuro2a tumor-bearing mice that are untreated, Fe3O4@gdPB nanoparticles + 
NIr laser-treated, or Fe3O4@gdPB nanoparticles + magnet + NIr laser-treated. (C–E) Tumor growth in Neuro2a-tumor bearing mice that are (C) untreated, (D) Fe3O4@
gdPB nanoparticles + NIr laser-treated, and (E) Fe3O4@gdPB nanoparticles + magnet + NIr laser-treated. each line represents a single tumor-bearing animal.
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observed to be statistically significant. Taken together, our 




@GdPB nanoparticles function as 
effective PTT agents resulting in slower tumor growth rates 
and increased survival relative to untreated mice although 
further studies are needed to identify the optimal modes for 
applying the external magnet and NIR laser.
Conclusion




@GdPB nanoparticles as effective 
theranostic agents, particularly for T1W imaging and PTT 





@GdPB nanoparticles that exhibited composite 




 and GdPB (Figures 1 and 2). The 
nanoparticles possessed the ability to function as effective 
contrast agents in both T1W and T2W scans (Figure 3) as 





nanoparticles generated cytotoxicity of targeted Neuro2a 
cells upon laser irradiation in vitro (Figure 5). Ex vivo imag-
ing studies demonstrated that the nanoparticles increased 
signal:noise ratios in T1W scans of tumor phantoms relative 
to controls (Figure 6). Finally, the nanoparticles functioned 
as effective PTT agents in vivo by decreasing tumor growth 
rate and increasing survival relative to untreated controls 
(Figure 7). Our findings demonstrate the theranostic util-




@GdPB nanoparticles and represent an 
important prelude to their eventual preclinical to clinical 
translation in treating cancer.
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Figure S1 representative TeM images of (A) Fe3O4 and (B) Fe3O4@gdPB nanoparticles as synthesized.
Note: The nanoparticles size analysis was performed using ImageJ by manually measuring the size of the individual nanoparticles from the TeM images, which yielded a mean 
particle diameter of 8.0±2.2 nm for Fe3O4 and 28.2±8.3 nm for Fe3O4@gdPB.
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